NEWS: Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, will sponsor a special reception during the J.P. Morgan 2016 Healthcare Conference, being held in San Francisco, Jan. 11-14. The conference, which is now in its 34th year, is an invitation-only event intended to create an environment of collaboration by bringing together stakeholders in the corporate, investor and financial sectors to learn about and explore market and sector trends.
“The J.P. Morgan Healthcare Conference offers a unique opportunity for companies across the healthcare sector to align with new and emerging technology,” said Patrick Witham, President & CEO of Paragon BioTeck, Inc. “We are excited to attend again, as we strive to advance this area of medicine.”
On January 12, in conjunction with its conference attendance, Paragon BioTeck will sponsor an invitation-only wine reception being hosted by the Oregon Bioscience Association, which is dedicated to developing growth in the biotechnology sector in Oregon. The event will feature select pinot noir vintages produced in Oregon, which is fast becoming known as one of the preeminent wine-making regions in the world.
The growth of the Oregon wine industry serves as the quintessential pairing for Oregon’s burgeoning biotechnology industry. Much like the Willamette Valley putting Oregon on the wine-making map, its biotechnology industry is becoming increasingly recognized for its important and lasting contributions to the evolving medical technology sphere.
About Paragon BioTeck, Inc.:
Paragon BioTeck, Inc., is a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies. Paragon’s portfolio of products is designed to protect and preserve eyesight and deliver comfort to the eyes. These products include the Comfortear(R) Lacrisolve(TM) 180 Absorbable Punctum Plug, Comfortear(R) Punctum Plug, EqualEyes(R) Ocular Lubricant, the preservative-free ilast(R) range of products and their FDA-approved Phenylephrine Hydrochloride Ophthalmic Solution, available in 2.5 interest and 10 interest.
More information: https://paragonbioteck.com/ .
Join the conversation on Facebook at https://www.facebook.com/ParagonBioTeck/ and Twitter @ParagonBioTeck.
This version of news story is Copr. © 2016 eNewsChannels™ (www.enewschannels.com) and the Neotrope® News Network – all commercial and reprint rights reserved. Unauthorized reproduction in whole or in part without express permission is prohibited.
